Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement

Dow Jones

03/16

By Adriano Marchese

Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement.

Shares traded 30% higher ahead of the morning bell at $4.26.

The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said.

The company aims to file an investigational new drug application for its lead candidate by mid-2027.

Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share.

The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share.

The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 16, 2026 07:17 ET (11:17 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2619245752"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619245752\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619245752?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619245752","market":"us","top_or_hot":-1,"title":"Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n</p>\n<p>\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n</p>\n<p>\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n</p>\n<p>\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n</p>\n<p>\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n</p>\n<p>\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-16 19:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n</p>\n<p>\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n</p>\n<p>\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n</p>\n<p>\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n</p>\n<p>\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n</p>\n<p>\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2619245752","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619245752","pubTimestamp":1773659820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement.Shares traded 30% higher ahead of the morning bell at $4.26.The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said.The company aims to file an investigational new drug application for its lead candidate by mid-2027.Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share.The stock has performed well so far in 2026, rising 55% since t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ABOS":"Acumen Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Acumen Pharmaceuticals因积极的阿尔茨海默病药物数据而股价上涨，私募3580万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n\n\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n\n\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n\n\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n\n\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n\n\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n\n\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 07:17 ET (11:17 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}